Related Experiment Video

Updated: Oct 5, 2026

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Regulation of PAI-1 concentration in platelets by systemic administration of antisense oligonucleotides to rats

Z Pawlowska1, E Chabielska, A Kobylanska

  • 1Department of Biophysics, Medical University in Lodz, Poland.

Thrombosis and Haemostasis
|July 4, 2001
PubMed

Insights

Antisense oligodeoxynucleotides targeting plasminogen activator inhibitor-1 (PAI-1) mRNA reduced PAI-1 levels and platelet aggregation in rats. This approach offers a novel strategy for managing arterial thrombosis by targeting platelet PAI-1.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • Plasminogen activator inhibitor-1 (PAI-1) plays a critical role in regulating fibrinolysis and is implicated in arterial thrombosis.
  • Elevated PAI-1 levels are associated with increased thrombotic risk and resistance to thrombolysis.
  • Targeting PAI-1 offers a potential therapeutic strategy for thrombotic disorders.

Purpose of the Study:

  • To investigate the efficacy of antisense oligodeoxynucleotides targeting PAI-1 mRNA in reducing PAI-1 concentration in rat platelets.
  • To evaluate the impact of antisense treatment on platelet function, including aggregability and thrombus formation in vivo.

Main Methods:

  • Administration of low doses of MPO-16R, an antisense oligodeoxynucleotide to PAI-1 mRNA, into rats.
  • Measurement of PAI-1 activity in rat blood plasma and platelet lysates.
  • Assessment of platelet count and platelet aggregability.
  • Evaluation of arterial thrombosis in an experimental rat model.

Main Results:

  • Low-dose MPO-16R significantly reduced PAI-1 activity in both plasma (20.5%) and platelet lysates (28.7%).
  • Platelet aggregability was significantly decreased in MPO-16R treated rats compared to controls (37% vs. 54%).
  • A significant delay in arterial occlusion time (31.8%) was observed in rats treated with MPO-16R, indicating reduced thrombus formation.

Conclusions:

  • Antisense oligodeoxynucleotides can effectively reduce platelet PAI-1 concentration and activity.
  • Targeting PAI-1 with antisense therapy demonstrates potential in mitigating platelet hyperaggregability and arterial thrombosis.
  • This study provides the first evidence for the successful reduction of platelet PAI-1 via an antisense approach, supporting its role in thrombosis therapy.

More Related Videos

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader07:13

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader

Published on: May 24, 2024

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation09:13

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

Published on: April 6, 2017

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...